Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (391-400 of 504) with videos related to

Pageof 51
Sort By:
Cancer Cell|August 17, 2010
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancerAhmed Ashour Ahmed, Zhen Lu, Nicholas B Jennings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemiaAaron D Schimmer, Elihu H Estey, Gautam Borthakur, et al.
Translational Oncology|February 3, 2022
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AMLKotoko Yamatani, Tomohiko Ai, Kaori Saito, et al.
Blood|March 2, 2017
More than 1 <i>TP53</i> abnormality is a dominant characteristic of pure erythroid leukemiaGuillermo Montalban-Bravo, Christopher B Benton, Sa A Wang, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
Leukemia|November 17, 2024
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasmsIan M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.
Oncotarget|June 5, 2018
Oxidized analogs of Di(1<i>H</i>-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activityMarisa Sanchez, Zebin Xia, Elizabeth Rico-Bautista, et al.
Blood|December 12, 2018
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemiaJan A Burger, Mariela Sivina, Nitin Jain, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
Science Advances|November 29, 2023
Enhanced <i>TP53</i> reactivation disrupts <i>MYC</i> transcriptional program and overcomes venetoclax resistance in acute myeloid leukemiasYuki Nishida, Jo Ishizawa, Edward Ayoub, et al.
Pageof 51

Showing results (391-400 of 504) with videos related to

Sort By:
Pageof 51
Cancer Cell|August 17, 2010
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancerAhmed Ashour Ahmed, Zhen Lu, Nicholas B Jennings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemiaAaron D Schimmer, Elihu H Estey, Gautam Borthakur, et al.
Translational Oncology|February 3, 2022
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AMLKotoko Yamatani, Tomohiko Ai, Kaori Saito, et al.
Blood|March 2, 2017
More than 1 <i>TP53</i> abnormality is a dominant characteristic of pure erythroid leukemiaGuillermo Montalban-Bravo, Christopher B Benton, Sa A Wang, et al.
American Journal of Hematology|January 5, 2017
Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantationSameh Gaballa, Rima Saliba, Betul Oran, et al.
Leukemia|November 17, 2024
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasmsIan M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.
Oncotarget|June 5, 2018
Oxidized analogs of Di(1<i>H</i>-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activityMarisa Sanchez, Zebin Xia, Elizabeth Rico-Bautista, et al.
Blood|December 12, 2018
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemiaJan A Burger, Mariela Sivina, Nitin Jain, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
Science Advances|November 29, 2023
Enhanced <i>TP53</i> reactivation disrupts <i>MYC</i> transcriptional program and overcomes venetoclax resistance in acute myeloid leukemiasYuki Nishida, Jo Ishizawa, Edward Ayoub, et al.
Pageof 51